- Email: [email protected]
Haemophilus influenzae D15 outer membrane protein production by vector plasmid DS-880-1-2 expression in host cell; chimeric antibody and DNA sequence; application as a recombinant vaccine
Potent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from 'Biotechnology Abstracts' with permission of Derwent Publications Ltd, Derwent House, 14 Great Queen Street, London WC2B 5DF, UK. Telephone 071 344 2800, Fax 071 344 2900.
Mycoplasma gallisepticum recombinant vaccine and DNA probe and DNA sequence; application in mycoplasma detection by hybridization Univ. Melbourne Au 9350 593; 26 May 1994 The following are claimed: an isolated polynucleotide of specified DNA sequence comprising a promoter region in the 5' conserved sequence of Mycoplasma gallisepticum; a method of producing a multivalent mycoplasma live vaccine vector, which involves placing at least one foreign antigen gene under the control of a promoter region from the 5' conserved sequence of M. gallisepticum, and obtaining expression of the foreign antigen gene; a multivalent live vaccine vector which comprises an attenuated mycoplasma strain, the genome of which encodes at least one foreign antigen under the control of the promoter region from the 5' conserved region of the p M G A gene, where the native mycoplasma antigen and at least one foreign antigen are expressed; and a detection system for mycoplasma, including detection of different strains within a species, where the detection system is a method which involves contacting a sample suspected of containing the mycoplasma with at least one nucleic acid probe specific for a mycoplasma under appropriate hybridization conditions for hybridization, and then detecting hybridization. 074-94
New vaccine strains of intestinal protozoon, e.g. Giardia are prepared by culture in medium containing bile, and produce toxin useful to immunize against protozoon infection; potential vaccine Univ. Technol. Int. Eur 600 396; 8 June 1994 A vaccine strain (1) of an intestinal protozoon in which the intestinal protozoon has been cultured in media containing bile so as to make it protectively immunogenic, is claimed. Also claimed are: i. preparation of the above strain; ii. a vaccine composition which upon in vivo administration provides protective immunity against an intestinal protozoon, the composition containing (I), a subunit of (I) or a toxin of the intestinal protozoon; iii. an isolated toxin (II) of an intestinal protozoon; iv. an antibody to (II); and v. a method of providing passive immunity in an animal susceptible to or suffering from an intestinal protozoal infection, which involves administering to the animal an antibody to (II). The intestinal protozoon is a Giardia, Crvpdtosporidium, Trichomonas, Histomonas, Spiromucellus, Entamoeba, Coccidia, Toxoplasma or Sarcocystis. (1) is preferably a strain of Giardia grown in TY1-S.33 media containing bile, thus providing a means for treating giardiasis. 075-94
Haemophilus influenzae D15 outer membrane protein production by vector plasmid DS-880-1-2 expression in host cell; chimeric antibody and DNA sequence; application as a recombinant vaccine Connaught Lab. World 9412 641; 9 June 1994 The following are new: (1) new nucleic acid (I) containing at 0264-410X/94/15/1481-01 ~ 1994 Butterworth-Heinemann Ltd
least a portion encoding Haemophilus influenzae D15 outer membrane protein (OMP) and having a sequence which is any of 5 (all 3000 bp) specified DNA sequences, or is hybridizable under stringent conditions with such sequences: (2) recombinant plasmids containing a segment of (I) at least 18 bp long, especially a recombinant vector DS-880-1-2 (ATCC 75605) encoding H. influenzae SB33 D15; (3) proteins (II) encoded by these plasmids; (4) purified D15 O M P (III); (5) synthetic polypeptides wiith sequences corresponding to (II) or (III); (6) antisera or antibodies specific for (II), (III) or immunogens containing them; and (7) chimeric molecules consisting of (II) or (III) bonded to another polypeptide, protein or polysaccharide. D I 5 0 M P can be produced easily on a large scale and is free of other antigens and lipo-oligosaccharides. (I), (II) and the synthetic polypeptides are useful in recombinant vaccines to protect against H. influenzae. D15 can also be used to induce immunity to abnormal polysaccharides on tumour cell and to generate antitumour antibodies for coupling to toxins, etc. 076-94
Attenuated strains of Aeromonas salmonicida useful as fish vaccine Univ. Victoria CA 2079 826; 6 April 1994 A new attenuated Aeromonas salmonicida has the identifying characteristics of strains 10S (ATCC 55357), 10SR (ATCC 55356) or 10SR-3 (ATCC 55355). Also new are (i) live vaccines for immunizing fish containing attenuated A. salmonicida that lack the A-layer (particularly a revertant of a membranecytochrome negative strain), and (ii) A. salmonieida A450-3 (ATCC 55354). The new strains, other than 10S which is an intermediate, are used in live vaccines to protect fish against virulent A. salmonicida (the causative against of salmonid furunculosis). Immunization is preferably by immersion in a vaccine-containing solution, but may also be by intraperitoneal injection. The vaccines can be released into the environment without significant risk of reversion to virulent form. Administration orally or by immersion is at least as effective as peritoneal administration of known vaccines. 077-94
Cattle leukaemia virus recombinant vaccine containing gp51 glycoprotein protein sequence; application as a booster vaccination Rhone Merieux Fr 2698 271; 27 May 1994 A vaccine against cattle leukaemia virus (CLV) contains as an active ingredient a peptide (I) corresponding to specified protein sequences of the gp71 viral glycoprotein, in a suitable vehicle or excipient. (I) is especially of the formula: (1) (Arg)3-Phe-GlyAla-Arg-Ala-Met-Val (Ia). Ser-Gln-Ala-Asp-Gln-Gly-Ser-PheTyr-Val-Asn-His-Gln-Ile-Leu-Phe-Leu-His-Leu-Lys (Ib), or Pro-Asp-Cys-Ala-Ile-Cys-Trp-Glu-Pro-Ser-Pro-Pro-Trp-AlaPro-Glu (Ic) (which is a synthetic peptide). The virus includes live, recombinant virus able to express (I), chimeric pseudo-viral particles lacking genetic material and carrying (I) on the surface, live mammal cell lines expressing (I), or ISCOM formulations containing (I). (I) is free of undesirable sequences, especially those that induce antibodies facilitating penetration of the virus into cells. It induces both a neutralizing B-lymphocyte response and an auxiliary T-lymphocyte response. The vaccine is especially useful as a booster (following primary vaccination with a live, recombinant virus expression both gp51 and gp30 of CLV). 078-94
Vaccine 1994 V o l u m e 12 N u m b e r 15
1481
Mycoplasma gallisepticum recombinant vaccine and DNA probe and DNA sequence; application in mycoplasma detection by hybridization Univ. Melbourne Au 9350 593; 26 May 1994 The following are claimed: an isolated polynucleotide of specified DNA sequence comprising a promoter region in the 5' conserved sequence of Mycoplasma gallisepticum; a method of producing a multivalent mycoplasma live vaccine vector, which involves placing at least one foreign antigen gene under the control of a promoter region from the 5' conserved sequence of M. gallisepticum, and obtaining expression of the foreign antigen gene; a multivalent live vaccine vector which comprises an attenuated mycoplasma strain, the genome of which encodes at least one foreign antigen under the control of the promoter region from the 5' conserved region of the p M G A gene, where the native mycoplasma antigen and at least one foreign antigen are expressed; and a detection system for mycoplasma, including detection of different strains within a species, where the detection system is a method which involves contacting a sample suspected of containing the mycoplasma with at least one nucleic acid probe specific for a mycoplasma under appropriate hybridization conditions for hybridization, and then detecting hybridization. 074-94
New vaccine strains of intestinal protozoon, e.g. Giardia are prepared by culture in medium containing bile, and produce toxin useful to immunize against protozoon infection; potential vaccine Univ. Technol. Int. Eur 600 396; 8 June 1994 A vaccine strain (1) of an intestinal protozoon in which the intestinal protozoon has been cultured in media containing bile so as to make it protectively immunogenic, is claimed. Also claimed are: i. preparation of the above strain; ii. a vaccine composition which upon in vivo administration provides protective immunity against an intestinal protozoon, the composition containing (I), a subunit of (I) or a toxin of the intestinal protozoon; iii. an isolated toxin (II) of an intestinal protozoon; iv. an antibody to (II); and v. a method of providing passive immunity in an animal susceptible to or suffering from an intestinal protozoal infection, which involves administering to the animal an antibody to (II). The intestinal protozoon is a Giardia, Crvpdtosporidium, Trichomonas, Histomonas, Spiromucellus, Entamoeba, Coccidia, Toxoplasma or Sarcocystis. (1) is preferably a strain of Giardia grown in TY1-S.33 media containing bile, thus providing a means for treating giardiasis. 075-94
Haemophilus influenzae D15 outer membrane protein production by vector plasmid DS-880-1-2 expression in host cell; chimeric antibody and DNA sequence; application as a recombinant vaccine Connaught Lab. World 9412 641; 9 June 1994 The following are new: (1) new nucleic acid (I) containing at 0264-410X/94/15/1481-01 ~ 1994 Butterworth-Heinemann Ltd
least a portion encoding Haemophilus influenzae D15 outer membrane protein (OMP) and having a sequence which is any of 5 (all 3000 bp) specified DNA sequences, or is hybridizable under stringent conditions with such sequences: (2) recombinant plasmids containing a segment of (I) at least 18 bp long, especially a recombinant vector DS-880-1-2 (ATCC 75605) encoding H. influenzae SB33 D15; (3) proteins (II) encoded by these plasmids; (4) purified D15 O M P (III); (5) synthetic polypeptides wiith sequences corresponding to (II) or (III); (6) antisera or antibodies specific for (II), (III) or immunogens containing them; and (7) chimeric molecules consisting of (II) or (III) bonded to another polypeptide, protein or polysaccharide. D I 5 0 M P can be produced easily on a large scale and is free of other antigens and lipo-oligosaccharides. (I), (II) and the synthetic polypeptides are useful in recombinant vaccines to protect against H. influenzae. D15 can also be used to induce immunity to abnormal polysaccharides on tumour cell and to generate antitumour antibodies for coupling to toxins, etc. 076-94
Attenuated strains of Aeromonas salmonicida useful as fish vaccine Univ. Victoria CA 2079 826; 6 April 1994 A new attenuated Aeromonas salmonicida has the identifying characteristics of strains 10S (ATCC 55357), 10SR (ATCC 55356) or 10SR-3 (ATCC 55355). Also new are (i) live vaccines for immunizing fish containing attenuated A. salmonicida that lack the A-layer (particularly a revertant of a membranecytochrome negative strain), and (ii) A. salmonieida A450-3 (ATCC 55354). The new strains, other than 10S which is an intermediate, are used in live vaccines to protect fish against virulent A. salmonicida (the causative against of salmonid furunculosis). Immunization is preferably by immersion in a vaccine-containing solution, but may also be by intraperitoneal injection. The vaccines can be released into the environment without significant risk of reversion to virulent form. Administration orally or by immersion is at least as effective as peritoneal administration of known vaccines. 077-94
Cattle leukaemia virus recombinant vaccine containing gp51 glycoprotein protein sequence; application as a booster vaccination Rhone Merieux Fr 2698 271; 27 May 1994 A vaccine against cattle leukaemia virus (CLV) contains as an active ingredient a peptide (I) corresponding to specified protein sequences of the gp71 viral glycoprotein, in a suitable vehicle or excipient. (I) is especially of the formula: (1) (Arg)3-Phe-GlyAla-Arg-Ala-Met-Val (Ia). Ser-Gln-Ala-Asp-Gln-Gly-Ser-PheTyr-Val-Asn-His-Gln-Ile-Leu-Phe-Leu-His-Leu-Lys (Ib), or Pro-Asp-Cys-Ala-Ile-Cys-Trp-Glu-Pro-Ser-Pro-Pro-Trp-AlaPro-Glu (Ic) (which is a synthetic peptide). The virus includes live, recombinant virus able to express (I), chimeric pseudo-viral particles lacking genetic material and carrying (I) on the surface, live mammal cell lines expressing (I), or ISCOM formulations containing (I). (I) is free of undesirable sequences, especially those that induce antibodies facilitating penetration of the virus into cells. It induces both a neutralizing B-lymphocyte response and an auxiliary T-lymphocyte response. The vaccine is especially useful as a booster (following primary vaccination with a live, recombinant virus expression both gp51 and gp30 of CLV). 078-94
Vaccine 1994 V o l u m e 12 N u m b e r 15
1481